BOSTON, Sept. 14, 2009 (GLOBE NEWSWIRE) -- Globalequityreport.com announces an investment report featuring bioscience company Genova Biotherapeutics Inc. The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Genova Biotherapeutics Inc. (OTCBB:GVBP) should be of particular interest to other bioscience companies: ViroPharma Inc. (Nasdaq:VPHM), SciClone Pharmaceuticals Inc. (Nasdaq:SCLN), Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM) and Dyax Corp. (Nasdaq:DYAX).
It is available at: http://globalequityreport.com/gvbp
Genova Biotherapeutics Inc. (OTCBB:GVBP) is a development stage bioscience company engaged in the discovery, development and commercialization of new bioscience technologies that fight infectious disease and cancer, particularly breast and prostate cancer. The Company's business strategy is to leverage cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then license these patented drug product candidates to major pharmaceutical and biotechnology companies such as Pfizer, Amgen, Myriad Genetics, Medarex and Biogen Idec.
To receive this FREE research report, visit and subscribe at: http://www.globalequityreport.com
About Globalequityreport.com
Globalequityreport.com is a leading stock web site that provides free alerts on stocks that are making big gains, as well as our weekly Newsletter, authored by The Market Timer. Globalequityreport.com also tracks small cap and hot penny stocks that we believe are on the brink of a massive upside. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on GlobalEquityReport, please visit us at http://www.globalequityreport.com
GlobalEquityReport Disclosure:
Globalequityreport.com is an independent electronic publication that provides information on selected publicly traded companies. Globalequityreport.com is not a registered investment advisor or broker dealer. Globalequityreport.com's affiliates, officers, directors and employees may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own due diligence before investing in any of the stocks mentioned above.